{"id":1650,"date":"2023-06-25T17:29:04","date_gmt":"2023-06-25T17:29:04","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/aspirin\/"},"modified":"2023-06-25T19:59:30","modified_gmt":"2023-06-25T19:59:30","slug":"aspirin","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/aspirin\/","title":{"rendered":"Aspirin"},"content":{"rendered":"

<\/p>\n

Aspirin<\/h1>\n

CLINICAL USE<\/h3>\n

NSAID:<\/p>\n

  • Analgesic and antipyretic<\/li>\n
  • Prophylaxis of cerebrovascular disease or myocardial infarction
    \n

    DOSE IN NORMAL RENAL FUNCTION<\/h3>\n<\/li>\n
  • Analgesia: 300 mg \u2013 1 g every 4 hours. Maximum 8 g daily in acute conditions<\/li>\n
  • Prophylaxis of cerebrovascular disease or myocardial infarction: 75\u2013300 mg daily
    \n

    PHARMACOKINETICS<\/h3>\n<\/li>\n
  • Molecular weight                           :180.2<\/li>\n
  • %Protein binding                           :80\u201390<\/li>\n
  • %Excreted unchanged in urine     : 2 (acidic urine); 30 (alkaline urine)<\/li>\n
  • Volume of distribution (L\/kg)       :0.1\u20130.2<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :2\u20133\/Unchanged
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function. See \u2018Other Information\u2019<\/li>\n
  • 10 to 20     : Dose as in normal renal function. See \u2018Other Information\u2019<\/li>\n
  • <10           : Dose as in normal renal function. See \u2018Other Information\u2019
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :Dialysed. Dose as in normal renal function<\/li>\n
  • HD                     :Dialysed. Dose as in normal renal function<\/li>\n
  • HDF\/high flux   :Dialysed. Dose as in normal renal function<\/li>\n
  • CAV\/VVHD      :Dialysed. Dose as in normal renal function
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n<\/li>\n
  • Potentially hazardous interactions with other drugs<\/li>\n
  • ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect, increased risk of nephrotoxicity and hyperkalaemia<\/li>\n
  • Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin \u2013 increased side effects; avoid with ketorolac \u2013 increased risk of side effects and haemorrhage<\/li>\n
  • Antibacterials: possibly increased risk of convulsions with quinolonesAnticoagulants: effects of coumarins enhanced; possibly increased risk of bleeding with heparins and coumarins<\/li>\n
  • Antidepressants: increased risk of bleeding with SSRIs and venlaflaxine<\/li>\n
  • Antidiabetic agents: effects of sulphonylureas enhanced<\/li>\n
  • Anti-epileptics: possibly increased phenytoin concentration<\/li>\n
  • Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir<\/li>\n
  • Ciclosporin: may potentiate nephrotoxicity<\/li>\n
  • Cytotoxic agents: reduced excretion of methotrexate; increased risk of bleeding with erlotinibDiuretics: increased risk of nephrotoxicity; antagonism of diuretic effect, hyperkalaemia with potassium-sparing diuretics<\/li>\n
  • Lithium: excretion decreased<\/li>\n
  • Pentoxifylline: increased risk of bleeding<\/li>\n
  • Tacrolimus: increased risk of nephrotoxicity
    \n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    \u2013<\/p>\n

    Comments<\/h4>\n

    \u2013<\/p>\n

    OTHER INFORMATION<\/h4>\n

    Aspirin at analgesic\/antipyretic dose is best avoided in patients with renal impairment, especially if severe<\/li>\n

  • Antiplatelet effect may add to uraemic gastrointestinal and haematologic symptoms<\/li>\n
  • Degree of protein binding reduced in ESRD<\/li>\n","protected":false},"excerpt":{"rendered":"

    Aspirin CLINICAL USE NSAID: Analgesic and antipyretic Prophylaxis of cerebrovascular<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1650","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1650"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1650\/revisions"}],"predecessor-version":[{"id":2883,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1650\/revisions\/2883"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}